Predictive Modeling Targets Thymidylate Synthase ThyX in Mycobacterium Tuberculosis

Hdl Handle:
http://hdl.handle.net/10144/613523
Title:
Predictive Modeling Targets Thymidylate Synthase ThyX in Mycobacterium Tuberculosis
Authors:
Djaout, K; Singh, V; Boum, Y; Katawera, V; Becker, H F; Bush, N G; Hearnshaw, S J; Pritchard, J E; Bourbon, P; Madrid, P B; Maxwell, A; Mizrahi, V; Myllykallio, H; Ekins, S
Journal:
Scientific Reports
Abstract:
There is an urgent need to identify new treatments for tuberculosis (TB), a major infectious disease caused by Mycobacterium tuberculosis (Mtb), which results in 1.5 million deaths each year. We have targeted two essential enzymes in this organism that are promising for antibacterial therapy and reported to be inhibited by naphthoquinones. ThyX is an essential thymidylate synthase that is mechanistically and structurally unrelated to the human enzyme. DNA gyrase is a DNA topoisomerase present in bacteria and plants but not animals. The current study set out to understand the structure-activity relationships of these targets in Mtb using a combination of cheminformatics and in vitro screening. Here, we report the identification of new Mtb ThyX inhibitors, 2-chloro-3-(4-methanesulfonylpiperazin-1-yl)-1,4-dihydronaphthalene-1,4-dione) and idebenone, which show modest whole-cell activity and appear to act, at least in part, by targeting ThyX in Mtb.
Publisher:
Nature Publishing Group
Issue Date:
10-Jun-2016
URI:
http://hdl.handle.net/10144/613523
DOI:
10.1038/srep27792
PubMed ID:
27283217
Submitted date:
2016-06-15
Language:
en
ISSN:
2045-2322
Appears in Collections:
TB

Full metadata record

DC FieldValue Language
dc.contributor.authorDjaout, Ken
dc.contributor.authorSingh, Ven
dc.contributor.authorBoum, Yen
dc.contributor.authorKatawera, Ven
dc.contributor.authorBecker, H Fen
dc.contributor.authorBush, N Gen
dc.contributor.authorHearnshaw, S Jen
dc.contributor.authorPritchard, J Een
dc.contributor.authorBourbon, Pen
dc.contributor.authorMadrid, P Ben
dc.contributor.authorMaxwell, Aen
dc.contributor.authorMizrahi, Ven
dc.contributor.authorMyllykallio, Hen
dc.contributor.authorEkins, Sen
dc.date.accessioned2016-06-16T22:13:33Zen
dc.date.available2016-06-16T22:13:33Zen
dc.date.issued2016-06-10en
dc.date.submitted2016-06-15en
dc.identifier.citationPredictive modeling targets thymidylate synthase ThyX in Mycobacterium tuberculosis. 2016, 6:27792 Sci Repen
dc.identifier.issn2045-2322en
dc.identifier.pmid27283217en
dc.identifier.doi10.1038/srep27792en
dc.identifier.urihttp://hdl.handle.net/10144/613523en
dc.description.abstractThere is an urgent need to identify new treatments for tuberculosis (TB), a major infectious disease caused by Mycobacterium tuberculosis (Mtb), which results in 1.5 million deaths each year. We have targeted two essential enzymes in this organism that are promising for antibacterial therapy and reported to be inhibited by naphthoquinones. ThyX is an essential thymidylate synthase that is mechanistically and structurally unrelated to the human enzyme. DNA gyrase is a DNA topoisomerase present in bacteria and plants but not animals. The current study set out to understand the structure-activity relationships of these targets in Mtb using a combination of cheminformatics and in vitro screening. Here, we report the identification of new Mtb ThyX inhibitors, 2-chloro-3-(4-methanesulfonylpiperazin-1-yl)-1,4-dihydronaphthalene-1,4-dione) and idebenone, which show modest whole-cell activity and appear to act, at least in part, by targeting ThyX in Mtb.en
dc.language.isoenen
dc.publisherNature Publishing Groupen
dc.rightsArchived with thanks to Scientific Reportsen
dc.titlePredictive Modeling Targets Thymidylate Synthase ThyX in Mycobacterium Tuberculosisen
dc.identifier.journalScientific Reportsen

Related articles on PubMed

All Items in MSF are protected by copyright, with all rights reserved, unless otherwise indicated.